the following is a summary of a presentation being roadshowed to us brokers.good to see the story being spread far and wide
regards -------------------------------------------- Corporate Summary Genetic Technologies Limited (ASX: GTG) (NASDAQ SmallCap: GENE(*)) is an emerging Australian life sciences company specializing in the fields of genetics and genomics. GTG owes its success to the visionary research of its founders, who demonstrated that non-coding DNA is an essential component of the regulatory function of all cells. This was contrary to the traditional scientific belief at that time, that non-coding DNA was merely accumulated historical debris, or “junk-DNA”. (*) – GENE is the code allocated to GTG for its forthcoming NASDAQ listing. GTG’s breakthrough research resulted in methods and processes through which the non-coding DNA of all multi-cellular species can be analyzed and applied. The resulting intellectual property is now patented in 24 countries around the world and forms the basis of GTG’s global licensing activities. In the last 3 years, GTG has signed 24 licenses (both research and commercial) around the globe for a total value in excess of A$35M. Importantly the average value of GTG’s commercial licenses has increased considerably as large, commercially significant companies are licensed. In 2005, the average value of a commercial license was in excess of A$5M with GTG having identified more than 400 commercially significant license opportunities in its current database. In addition to its growing patent licensing program, GTG has developed Australia’s largest private DNA testing laboratory providing a range of genetic testing services across humans, animals and plants. GTG is now in the unique position to expand this business through the access it gains to a licensee’s intellectual property during the licensing process. Through its expanding range of DNA testing services, GTG aims to become the No. 1 private DNA testing laboratory in the Asia Pacific region. Investment Highlights Revenue generating license arrangements: Genetic Technologies licensing program is on the threshold of major growth. In addition to licenses with major US Biotechs such as Genzyme Corp and MetaMorphix Inc, GTG’s patent definitions were recently supported by the courts in a Markman hearing against Applera Corporation. These achievements provide GTG with significant commercial strength to globally increase the rate of its patent licensing activities. To date this program has generated A$35M in value which includes recurring licensing fees in excess of A$1.25M per annum. Targeted licensing process in place: GTG has a current database comprising over 2,000 leads, ranked according to potential commercial and strategic value. Through the careful identification of targets, GTG has been able to rapidly increase the value of each commercial license granted, not only in terms of cash, but also via access to IP owned by the licensee that might be valuable to GTG’s DNA testing business. Expanding DNA testing business: GTG owns and operates Australia’s largest independent DNA testing laboratory, performing genetic tests across humans, animals and plants. GTG is Australia’s only accredited non-government forensics laboratory and is the market leader in the provision of human parentage tests. GTG is also rapidly becoming the largest provider of DNA testing services to the sheep, cattle and dog industries. Current revenues from its DNA service testing business exceed A$3.5M per annum which is forecast to grow significantly as additional tests are rolled out to the market. Global testing opportunities: GTG has recently secured the global rights to the ACTN3 SportsGene™ test that examines “muscle twitch” performance. The test can identify whether a person may be naturally geared to sprint/power events, or towards endurance events. The ACTN3 SportsGene™ test is suitable for athletes and sports people of all ages. GTG is currently negotiating marketing and distribution rights in Europe, the US, Japan and the Asia Pacific region. Research projects: GTG has 5 major research projects that provide the basis for future growth. In particular, GTG’s RareCellect® project has the potential to provide GTG with significant revenues. Using RareCellect’s® patented technology, GTG is able to isolate fetal cells from maternal blood. These cells can then be tested for genetic abnormalities such as Downs Syndrome and Cystic Fibrosis. By only requiring a simple blood test from the mother, the RareCellect® technology renders risky procedures such as amniocentesis and chorionic villus testing redundant while having the added advantage of being able to be undertaken much earlier in pregnancy. Strong financial position: GTG has a solid balance sheet, which includes A$20M in cash. For the six months to December 2004, GTG was cash flow positive which included the cash outflows associated with its research projects. Experienced management team: GTG’s executive team, led by Executive Chairman Dr. Mervyn Jacobson M.B.B.S, has extensive international experience in the development and management of emerging businesses. The business is managed in four divisions, covering Licensing, Corporate, Science and New Business with each divisional head reporting to the Executive Chairman. Segments 2005 Goals NASDAQ SmallCap listing using Level II American Depositary Receipts (ADRs) Resolution of Applera lawsuit Further global license agreements Expansion of Australian DNA testing business with emphasis on animals and forensics Global roll out of the ACTN3 SportsGene™ test To expand GTG’s business through global collaborations and possibly acquisitions Financial Highlights 01234562002200320042005Calendar YearA$MAverage Annual Value of Commercial Licenses Genetic Technologies Limited 60-66 Hanover Street Fitzroy, Victoria 3065 Australia Ph: 011 613 9415 1135 www.gtg.com.au Contacts Geoff Newing – Investor Relations [email protected] Lippert/Heilshorn & Associates 800 Third Ave., 17th Floor New York, NY 10022 Ph: (212) 838 3777 www.lhai.com Contacts Kim Sutton Golodetz Lisa Lindberg [email protected][email protected] Contact Information Lippert/Heilshorn & Associates 1900 Ave. of the Stars, Suite 2840 Los Angeles, CA 90067 Ph : (310) 691-7100 www.lhai.com Contacts Bruce Voss [email protected] The information contained herein was obtained from the management of Genetic Technologies and other sources Lippert/Heilshorn &Associates (LHA) believes to be reliable. This does not constitute the solicitation of the purchase or sale of securities. LHA has beenengaged by Genetic Technologies Limited as its investor relations firm. Except for the historical `information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. May 2005
GTG Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
